INTERFACE BIOLOGICS, INC. (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices.

Our primary technology focus areas are anti-thrombogenic additives that reduce thrombosis and programmable combination drug delivery devices.

The company was founded in 2001 based on the work of Dr. Paul Santerre at the University of Toronto. The name, Interface Biologics, comes from the critical interface between the human body and medical devices at the molecular level.



Leave a comment

February 22, 2013 · 6:44 pm

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s